System and method for analysis of bio-metabolites for-use in image-guided surgery
A system for identifying a bio-marker using mass spectroscopy is provided that includes a sample receptacle configured to receive a tissue sample, a mass spectrometry apparatus configured to receive the tissue sample and analyze the tissue sample using a mass spectrometry process to generate mass spectrometry data, and a computer system that includes a computer processor having access to a non-transitory, computer-readable storage medium having stored thereon instructions. The instructions cause the computer processor to: receive the mass spectrometry data from the mass spectrometry apparatus; analyze the mass spectrometry data to determine a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample; and generate a report indicating a health of the tissue sample based on the presence of 2-HG in the tissue sample.
1. A system for identifying a bio-marker using mass spectroscopy, the system comprising:
a sample receptacle configured to receive a tissue sample;
a mass spectrometry apparatus configured to receive the tissue sample and analyze the tissue sample using a mass spectrometry process to generate mass spectrometry data; and
a computer system including a computer processor having access to a non-transitory, computer-readable storage medium having stored thereon instructions that cause the computer processor to:
receive the mass spectrometry data from the mass spectrometry apparatus;
analyze the mass spectrometry data to determine a relative abundance of a mass-to-charge ratio of about 147 m/z and a relative abundance of a mass-to-charge ratio of about 129 m/z, thereby indicating a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample; and
generate a report indicating a likelihood of cancer in the tissue sample based on the presence of 2-HG in the tissue sample.
2. The system of claim 1 , wherein the computer system further includes instructions that cause the computer processor to analyze the mass spectrometry data to further characterize 129 m/z and determine the relative abundance of 101 m/z and 85 m/z indicating a presence of 2-HG in the tissue sample.
3. The system of claim 1 , wherein the computer system further includes instructions that cause the computer processor to analyze the mass spectrometry data to determine a relative abundance of 103 m/z and 89 m/z indicating a presence of a wild-type isocitrate dehydrogenase 1 (IDH1) in the tissue sample.
4. The system of claim 1 , further comprising a report generator configured to deliver the report indicating the health of the tissue.
5. The system of claim 1 , further comprising a database of data about bio-markers and wherein the computer system further includes instructions that cause the computer processor to access the database and compare the mass spectrometry data to the data about bio-markers to determine the presence of 2-Hydroxyglutarate (2-HG) in the tissue sample.
6. The system of claim 5 , wherein the computer system further includes instructions that cause the computer processor to determine relative abundance of at least 147 m/z to determine the presence of 2-Hydroxyglutarate (2-HG) in the tissue sample.
7. The system of claim 1 , wherein the mass spectrometry apparatus includes a desorption electrospray ionization apparatus.
8. The system of claim 1 , further comprising a tracking system arranged to correlate a spatial location the tissue sample was removed from with the mass spectrometry data.
9. The system of claim 8 , further comprising a report generator configured to display the spatial location and a report indicating the likelihood of the presence of 2-HG each spatial location in the tissue sample.
10. A method of identifying cancerous cells, the method comprising:
collecting a tissue sample;
analyzing the tissue sample with a mass spectrometry system;
determining a relative abundance of a mass-to-charge-ratio of about 147 m/z;
determining a relative abundance of a mass-to-charge ratio of about 129 m/z; and
based at least in part on the determined relative abundance of 147 m/z, generating a report indicating a likelihood that the tissue sample includes cancerous cells.
11. The method of claim 10 , further comprising characterizing the 129 m/z to determine a relative abundance of a mass-to-charge-ratio of about 101 m/z and 85 m/z.
12. The method of claim 10 , further comprising determining a relative abundance of a mass-to-charge-ratio of about 103 m/z and 89 m/z.
13. The method of claim 10 , further comprising:
determining a relative abundance of a mass-to-charge-ratio of about 129 m/z;
characterizing the 129 m/z to determine a relative abundance of a mass-to-charge-ratio of about 101 m/z and 85 m/z;
determining a relative abundance of a mass-to-charge-ratio of about 103 m/z and 89 m/z; and
based at least in part on the determined relative abundance of 129 m/z, 103 m/z, 101 m/z, 89 m/z, and 85 m/z, determining whether the tissue sample includes cancerous cells.
14. The method of claim 13 , further comprising indicating a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample if the relative abundances of 129 m/z, 101 m/z, and 85 m/z are equal to or greater than predetermined levels.
15. The method of claim 13 , further comprising indicating a presence of a wild-type isocitrate dehydrogenase 1 (IDH1) in the tissue sample if the relative abundances of 103 m/z and 89 m/z are equal to or greater than predetermined levels.
16. A system for use in an operating room, the arrangement comprising:
a sampling probe configured to collect a tissue sample;
a mass spectrometry apparatus in communication with the sampling probe and configured to receive the tissue sample and analyze the tissue sample using a mass spectrometry process to generate mass spectrometry data;
a computer system including a computer processor having access to a non-transitory, computer-readable storage medium having stored thereon instructions that cause the computer processor to:
receive the mass spectrometry data from the mass spectrometry apparatus;
analyze the mass spectrometry data to determine a relative abundance of 147 m/z indicating a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample;
access a database of at least one of bio-marker information and bio-marker analysis algorithms; and
analyze the relative abundance of 147 m/z using the at least one of the bio-marker information and bio-marker analysis algorithms to determine a presence of 2-HG in the tissue sample; and
a report generator configured to deliver a report indicating the likelihood of cancer in the tissue sample.
17. The system of claim 16 , wherein the computer system further includes instructions that cause the computer processor to: determine a relative abundance of a mass-to-charge-ratio of about 129 m/z; characterize the 129 m/z to determine a relative abundance of a mass-to-charge-ratio of about 101 m/z and 85 m/z; determine a relative abundance of a mass-to-charge-ratio of about 103 m/z and 89 m/z; and indicate a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample if the relative abundances of 129 m/z, 101 m/z, and 85 m/z are equal to or greater than predetermined levels.
18. The system of claim 16 , wherein the computer system further includes instructions that cause the computer processor to: determine a relative abundance of a mass-to-charge-ratio of about 129 m/z; characterize the 129 m/z to determine a relative abundance of a mass-to-charge-ratio of about 101 m/z and 85 m/z; determine a relative abundance of a mass-to-charge-ratio of about 103 m/z and 89 m/z; and indicate a presence of a wild-type isocitrate dehydrogenase 1 (IDH1) in the tissue sample if the relative abundances of 103 m/z and 89 m/z are equal to or greater than predetermined levels.